Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Autobone and Bioactive Glass With Ridge Splitting

1. Mai 2021 aktualisiert von: Walid Elamrousy, Kafrelsheikh University

Ridge Splitting and Simultaneous Implant Placement With Autogenous Bone and Bioactive Glass for the Treatment of Maxillary Horizontal Bone Defects: A Randomised Clinical Trial

Objective: To compare the use of autogenous bone graft versus autogenous bone graft mixed with bioactive glass bone graft in the treatment of maxillary anterior horizontal bone defects by ridge splitting technique combined with simultaneous implant placement.

Materials and methods: Twenty-two patients were divided randomly into two groups; control group and study group. In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect. In both groups, the implants were inserted simultaneously with ridge splitting. 6 months after implant placement, the mean bone width and alveolar bone loss values were evaluated. Statistical analysis using paired Student's t- test to compare results within the same group of patients, whereas, independent samples t-test was used to compare variables between the two groups

Studienübersicht

Detaillierte Beschreibung

Participants' selection:

22 patients, aged from 18 to 50 years, were selected in this prospective, randomized and blinded clinical trial from the Outpatient Clinic of the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Kafrelsheikh University. Those subjects had inadequate bone volume for implant placement due to width insufficiency of maxillary anterior alveolar ridges. The research ethical committee of Faculty of Dentistry, Kafrelsheikh University approved the study (KD/06/21). Research procedures were explained to all patients, and they agreed to participate in the study and signed the appropriate informed consent form. The inclusion criteria implemented for patient selection were good general health at the time of surgery; at least 3months postextraction healing period; and horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone height). The criteria of patients exclusion were vertical bone defect; thick labial cortex with less cancellous bone inside; obvious undercut on the labial/buccal side; uncontrolled periodontal conditions; history of radiotherapy in the head and neck region; uncontrolled diabetes mellitus or other systematic disorders; smokers; pregnancy; non-compliant patients; and allergic reaction to the used medications.

Pre-surgical therapy and grouping Pre-surgical therapy consisted of a thorough full-mouth scaling and root planning. Patients were randomly assigned immediately before surgery into two groups (11 patients each) by computer-assessed randomization software (Random Allocation Software, Version 1.0). Control group received ridge splitting with simultaneous implant placement in combination with autogenous bone graft alone, while study group used (1:1) mixture of autogenous and bioactive glass bone grafts. Bone volume was assessed two weeks before operation using CBCT (Scanora 3D, Soredex Oy, Tuusula, Finland).

Surgical procedure:

Operations were performed under local anesthesia. Mid-crestal incision followed by full thickness flap reflection to expose surgical site. Mid crestal cut using piezo-surgery unit (Piezotome® Cube, ACTEON®, Acteon Group Ltd, Norwich, England). Then, the cut was extended deep to the length of implant. Then, ridge was expanded progressively using bone wedges (Microdent Implant System, Spain). Implant location was marked, with a buccal bony wall as uniformly thick (>1 mm) as possible to avoid bone fracture. The implant site was prepared and 3.75*13 mm dental implant fixture (Humana Dental Implants & Accessories GmbH, Germany) was placed stably in between the two bony plates.

Autogenous bone harvesting:

Incision was made at mucogingival junction in the symphysis area followed by full thickness flap reflection, and then corticocancellous bone was harvested using a trephine drill. Finally the flap was sutured by interrupted and horizontal mattress suture by 3-0 black silk.

In control group, harvested autogenous bone graft was used for augmentation of the gap between buccal and lingual plates. Study group received the same way of treatment except using (1:1) mixture of the harvested autogenous bone with bioactive glass bone graft (BonyGlass, Pharma-Excellence, Egypt). The wound was completely closed in a tension-free way. All surgeries were performed by the same operator.

Postoperative care:

Patients were prescribed amoxicillin-clavulanic acid 1g. every 12hours antibiotic (Augmentin 1g, SmithKline Beecham Pharmaceuticals), and 0.12% chlorhexidine hydrochloride mouth wash twice daily (Hexitol, ADCO, Cairo, A.R.E). The sutures were removed 14days postoperatively. No removable denture was allowed to wear for 2weeks.

6months postoperatively, clinical evaluation was recorded including implant survival, presence of infection, pain, tenderness or wound dehiscence. CBCT was taken at 6months postoperatively to evaluate ridge width and bone level. All clinical and radiographic measurements were recorded by one calibrated masked examiner.

Study variables The primary outcome variable was linear changes in the marginal bone surrounding the implants and alveolar ridge width, taken from cross-sectional and longitudinal CBCT images. Bone heights and width were assessed preoperatively and after 6months postoperatively using the CBCT images.

Statistical analysis:

Sample size calculation was undertaken via G power version 3.1 statistical software based on the following pre-established parameters: an alpha-type error of 0.05, a power test of 0.80, a total sample of 22 subjects (11 subjects for each group) appeared to be sufficient.

The statistical analysis was performed using IBM SPSS version 20 software (IBM Corp., Armonk, NY, USA). Data were presented as the mean+stanstandard deviation. The paired Student's t- test was used to compare the obtained results within the same group of patients at 2 different intervals. The independent samples t-test was used to compare variables between the two groups. In all tests, the result was considered statistically significant if the P-value was <0.05.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

22

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Kafr Ash Shaykh, Ägypten, 214312
        • Faculty of Dentistry, Kafrelsheikh University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

21 Jahre bis 50 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • good general health at the time of surgery
  • at least 3months postextraction healing period
  • horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone vertical height).

Exclusion Criteria:

  • vertical bone defect
  • thick labial cortex with less cancellous bone inside
  • obvious undercut on the labial/buccal side
  • uncontrolled periodontal conditions
  • history of radiotherapy in the head and neck region
  • uncontrolled diabetes mellitus or other systematic disorders
  • smokers
  • pregnancy
  • non-compliant patients
  • allergic reaction to the used medications.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: autogenous bone graft
autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
Experimental: mix of bioactive glass and autogenous bone graft
1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical measurements of pain intensity
Zeitfenster: 6 months
pain intensity verbal rating scale either mild, moderate or sever
6 months
Clinical incidence of implants mobility
Zeitfenster: 6 months
Implants mobility
6 months
measuring the survival rates
Zeitfenster: 6 months
survival rates of implants
6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
radiographic results of bone width and height
Zeitfenster: 6 months
evaluation of bone width and height using CBCT
6 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. April 2020

Primärer Abschluss (Tatsächlich)

10. April 2021

Studienabschluss (Tatsächlich)

15. April 2021

Studienanmeldedaten

Zuerst eingereicht

16. März 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. März 2021

Zuerst gepostet (Tatsächlich)

24. März 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. Mai 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. Mai 2021

Zuletzt verifiziert

1. Mai 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • RSBG2021

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren